Peter G. Schultz, Ph.D.
Scripps Family Chair Professor
Department of Chemistry
The Scripps Research Institute
Monday, February 6, 2012
A Chemist's Foray into Translational Medicine
Dr. Schultz and his team are using a variety of cell based screens to identify and characterize the mechanisms of small molecules that affect stem cell self renewal and differentiation, and the reprogramming of somatic cells. During his presentation, examples of this will be discussed including the expansion of cord blood derived HSCs, in vivo neurogenesis, the selective differentiation of MSCs to chondrocytes and osteoblasts, reversible beta cell proliferation, MEF reprogramming, human ESC self renewal and differentiation, and the selective killing of cancer stem cells.
About Peter G. Schultz
Peter G. Schultz did his undergraduate and graduate work at the California Institute of Technology. His thesis work with Peter Dervan resulted in the first synthetic molecules (polypyrroleamides) that sequence-selectively cleave DNA. In 1985, after postdoctoral studies at the Massachusetts Institute of Technology with Chris Walsh, he joined the faculty of the University of California at Berkeley where he was Professor of Chemistry, Principal Investigator at Lawrence Berkeley National Laboratory and an Investigator of the Howard Hughes Medical Institute.
Dr. Schultz joined the faculty of Scripps in 1999 where he is currently the Scripps Professor of Chemistry. He founded and was the Institute Director of the Genomics Institute of Novartis Research Foundation (GNF) from 1999 to 2010. In addition, Dr. Schultz is a founder of Affymax Research Institute, Syrrx, Kalpsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx and Wildcat Technologies.
Awards include the Waterman Award of the National Science Foundation, membership in the National Academy of Sciences and National Institute of Medicine, the 1994 Wolf Prize in Chemistry, the 2003 Paul Ehrlich Prize, and the 2005 Arthur C. Cope Award of the American Chemical Society.
Register now for SLAS2012.
The SLAS2012 Scientific Program Crosses a Diversity of Industries:
Jing Cheng, Ph.D.
Member, Chinese Academy of Engineering
Director, National Engineering Research Center for Beijing Biochip Technologies
CEO, CapitalBio Corporation
Cheung Kong Professor, Department of Biomedical Engineering, Tsinghua University School of Medicine, Beijing, China
Tuesday, February 7, 2012
Biochips for Translational Medicine
CapitalBio, China's advanced diagnostics powerhouse, has been developing biochip technologies and products for 10 years in collaboration with leading research hospitals in China to satisfy unmet demands from hospital bedsides. The products that have been certified by China SFDA including a DNA microarray analyzing nine mutations in four human genomic and mitochondrial genes account for approximately 80 percent of the causes of inherited deafness, including susceptibility to deafness induced by exposure to aminoglycoside antibiotics, and a protein array for autoimmune disease diagnosis. In addition, two chips that can provide rapid sample-to-answer results in only 6 hours have also been developed, one chip identifies 17 different mycobacteria and the second chip detects the resistance to two first line drugs, Rifampicin and Isoniazid. These two multi-facet TB tests are certified by both the China SFDA and the European Community (CE mark). A number of other close to market products include a HBV drug resistance detection array for Lamivudine and Adefovir, a microfluidic chip for the identification of 12 major bacterial-associated respiratory infections in two hours. Active biochip technologies for fertility and reproductive health will be discussed. A full line of instruments from sample processing to detection of results will also be presented.